UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding UNCY investors of a securities fraud class action and a November 2, 2026 lead plaintiff deadline for the December 29, 2025 to June 29, 2026 class period. The underlying complaint alleges Unicycive made false and misleading statements, including failure to inspect its third-party manufacturing partner for GMP compliance and lack of support for claims that FDA-identified vendor deficiencies were resolved. This is law-firm marketing rather than an issuer disclosure; the class has not been certified and no settlement or recovery amount exists.
Key figures
- Class period
- December 29, 2025 to June 29, 2026
- Statutory claims
- Sections 10(b) and 20(a) of the Securities Exchange Act of 1934; Rule 10b-5
- Lead plaintiff deadline
- November 2, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.